US EditionWHO Issues First Guidelines for GLP-1 Obesity Treatments
WHO conditionally recommends GLP-1 drugs for obesity treatment but warns fewer than 10% of eligible people will access them due to cost and health system limits.
- On Monday, the World Health Organization recommended GLP-1 drugs as a tool to manage obesity in adults, publishing guidance in JAMA defining long-term use as six months or more.
- Regulatory approvals, including by the Food and Drug Administration, preceded the guidance drafted by a committee of obesity, pharmacology and public-health experts at the request of WHO member states amid debate in recent years.
- GLP-1 drugs work by mimicking a hormone that signals fullness and reduce appetite to help people lose weight, while more than 890 million adults worldwide are obese and obesity causes 3.7 million deaths annually.
- The recommendation is conditional, the WHO said, as benefits likely outweigh downsides but more long-term safety and efficacy data, plus lower prices, are needed to address access and pricing concerns.
- In the U.S., one in eight adults report currently taking a GLP-1 drug amid the societal shift in obesity framing and WHO urging public-health coordination.
176 Articles
176 Articles
GLP-1 drugs may reach fewer than one in 10 people who need them, experts predict
NEWYou can now listen to Fox News articles! The World Health Organization (WHO) has announced its official guidance on the use of GLP-1 drugs for treating obesity. GLP-1 drugs are medications that mimic the natural hormone glucagon-like peptide-1 (GLP-1), which are most commonly used for type 2 diabetes and medical weight loss. The first guideline, released on Dec. 1, aims to address the “growing global health challenge of obesity,” WHO wrote in…
Ghebreyesus argues that new guidelines "recognize that obesity is a chronic disease that can be treated with comprehensive care and life-long".
InsideNoVA.com
WHO Issues First Guidance on Using GLP-1 Drugs to Treat Obesity
Key Takeaways
The World Health Organization (WHO) draws attention to the fact that new injectable treatment of obesity is still far from being accessible on a large scale, less than 10% of eligible people are able to obtain it. Under conditions where more than one billion people are currently under global burden, and estimates indicate that, without additional measures, more than two billion people will be subject to access to GLP-1 by 2030, WHO requests addi…
Coverage Details
Bias Distribution
- 49% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
